LPL Financial
ALGS icon

LPL Financial’s Aligos Therapeutics ALGS Stock Holding History

LPL Financial’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,500
Closed -$383K – 6207
2026
Q1 		$383K Sell
51,500
-14,500
-22% -$110K ﹤0.01% 5007
2025
Q4 		$615K Buy
66,000
+10,880
+20% +$103K ﹤0.01% 4537
2025
Q3 		$540K Buy
55,120
+25,020
+83% +$229K ﹤0.01% 4556
2025
Q2 		$217K Buy
+30,100
New +$180K ﹤0.01% 5029

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial's ALGS Position: Q2 2026 in Review

LPL Financial sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 51,500 shares — an estimated $383K sold.

LPL Financial first reported a position in ALGS in Q2 2025 and held it in 4 quarters. The position peaked at $615K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • LPL Financial reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • LPL Financial sold 51,500 Aligos Therapeutics shares in Q2 2026, an estimated $383K.
  • LPL Financial first reported a position in Aligos Therapeutics in Q2 2025 and held it in 4 quarters.
  • LPL Financial's Aligos Therapeutics position peaked at $615K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.